Behavioural Intervention
THRIVE 2.0 Program for Preventing Childhood Obesity
This trial tests an obesity prevention program for infants & caregivers of color &/or from low-income backgrounds. The aim is to prevent rapid infant weight gain & assess feasibility/acceptability. Participants receive 4 prevention sessions & assessments at baseline, post-treatment & follow-up.
Popular Filters
Trials for Obesity Patients
Behavioural Intervention
CBT for Insomnia in Breast Cancer Survivors
This trial will compare two treatments for overweight/obese women with early stage breast cancer and insomnia: one with an insomnia intervention before weight loss, and one with sleep education before weight loss. Outcomes will be measured at various time points.
Integrase Strand Transfer Inhibitor
Dolutegravir + Tenofovir Alefenamide Metabolic Effects in Healthy Volunteers
This trial studies how a common HIV drug affects how the body uses energy. Healthy adults aged 18-55 can take part. Tests include measuring oxygen intake, X-rays, and laser scans.
Trials for Metabolic Syndrome Patients
Behavioural Intervention
CBT for Insomnia in Breast Cancer Survivors
This trial will compare two treatments for overweight/obese women with early stage breast cancer and insomnia: one with an insomnia intervention before weight loss, and one with sleep education before weight loss. Outcomes will be measured at various time points.
Integrase Strand Transfer Inhibitor
Dolutegravir + Tenofovir Alefenamide Metabolic Effects in Healthy Volunteers
This trial studies how a common HIV drug affects how the body uses energy. Healthy adults aged 18-55 can take part. Tests include measuring oxygen intake, X-rays, and laser scans.
Trials With No Placebo
Integrase Strand Transfer Inhibitor
Dolutegravir + Tenofovir Alefenamide Metabolic Effects in Healthy Volunteers
This trial studies how a common HIV drug affects how the body uses energy. Healthy adults aged 18-55 can take part. Tests include measuring oxygen intake, X-rays, and laser scans.
Atypical Antipsychotic
Risperidone vs Aripiprazole for Weight Gain in Children with Autism
This trial is comparing two medicines, aripiprazole and risperidone, to see which one causes more weight gain in children with autism. The study focuses on children under 18 who have behavior problems like irritability and aggression. These medicines help by calming brain activity to improve behavior. The main goal is to find out which medicine leads to less weight gain over a few months. Aripiprazole and risperidone are both FDA-approved for treating irritability in children with autism.
View More Related Trials
Frequently Asked Questions
Introduction to weight gain
What are the top hospitals conducting weight gain research?
When it comes to understanding and addressing weight gain, several hospitals are taking on the challenge through clinical trials. In Baton Rouge, Louisiana, the Pennington Biomedical Research Center leads the pack with two ongoing weight gain trials and a total of seven studies dedicated to this area. Their first recorded trial dates back to 2008, showcasing their long-standing commitment to researching ways in which we can better understand and combat weight gain.
Moving eastward to Little Rock, Arkansas Children's Nutrition Center is making strides with one active weight gain trial and one completed study so far. Fascinatingly enough, this center only recently initiated its first-ever weight gain trial in 2023—a testament to their dedication towards exploring new avenues for combating this widespread issue.
Sibley Memorial Hospital in Washington also joins the ranks by conducting an ongoing weight gain trial alongside one previous study conducted since embarking on their journey into researching this subject matter in 2023. Similarly located in Baltimore is the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins—specifically, the Avon Foundation Breast Center—who has taken up the mantle of investigating weight gain as well. With one active trial currently underway and a single prior study completed since initiating research efforts just last year (in 2023), they have already made significant contributions within a short span of time.
Lastly, another institution within Johns Hopkins Medicine system called Johns Hopkins Bayview Medical Center proves itself as yet another force actively involved with tackling issues related to weight management by conducting its own ongoing clinical investigation while having accomplished an all-time record of accomplishing previous inquiry around same topic just like other counterparts mentioned above from specific year onwards i.e., starting point being identical - 2023.
These hospitals collectively serve as beacons of hope for those struggling with weight-related concerns while emphasizing that research endeavors continually push boundaries towards unlocking effective solutions for managing healthy body weights. As these institutions dedicate resources and expertise into comprehending complex factors contributing to weight gain, we inch closer to a future where the battle against excess weight becomes more manageable and individual well-being is prioritized.
Which are the best cities for weight gain clinical trials?
When it comes to weight gain clinical trials, several cities are at the forefront of research. In Baltimore, Maryland, there are 5 active trials focusing on interventions like Cognitive-Behavioral Therapy for Insomnia (CBT-I) and Healthy for Two/Healthy for You. Houston, Texas also offers 4 ongoing studies exploring treatments such as Exenatide and Nutritional Intervention. Similarly, New york City has 4 active trials investigating interventions like tenofovir alafenamide/lamivudine and New Infant Formula. Additionally, Washington D.C., with its 3 active trials, explores options like Cognitive-Behavioral Therapy for Insomnia (CBT-I) and OLZ/SAM. Lastly, Chapel Hill in North carolina boasts 3 ongoing studies examining interventions ranging from Activity Intervention to Centering Appetite Intervention. These cities provide individuals seeking weight gain solutions access to cutting-edge clinical trials that contribute to our understanding of effective strategies in this area.
Which are the top treatments for weight gain being explored in clinical trials?
In the realm of weight gain research, clinical trials are exploring some promising treatments. One such intervention is currently being tested in two active trials and has been a part of three weight gain trials since 2013. Another potential solution is Cognitive-Behavioral Therapy for Insomnia (CBT-I), which is currently being studied in one ongoing trial and was first listed as a treatment option in 2023. Lastly, tenofovir alafenamide shows promise with its involvement in one active trial and previous inclusion in one weight gain trial since its listing also in 2023. These innovative approaches offer hope for individuals struggling with weight gain, bringing us closer to finding effective solutions that can improve their quality of life.
What are the most recent clinical trials for weight gain?
Recent clinical trials have shed light on potential interventions for weight gain. One promising approach is the use of semaglutide administered through a pen injector, which has shown positive results in Phase 2 trials. Another trial investigated the efficacy of Biktarvy, specifically targeting weight gain as one of its endpoints in Phase 4 studies. Additionally, a study involving exenatide, NRT (Nicotine Replacement Therapy), and smoking cessation counseling explored their impact on weight gain during quitting attempts. Lastly, research into OLZ/SAM and treatment with risperidone aims to better understand strategies to address weight gain associated with these medications. These recent developments provide hope for individuals seeking effective solutions to manage or prevent unwanted weight gain.
What weight gain clinical trials were recently completed?
Recent clinical trials exploring weight gain have yielded promising results, offering insights into potential interventions. In March 2022, Aardvark Therapeutics, Inc., successfully completed a trial investigating the efficacy of ARD-101. Similarly, Corcept Therapeutics concluded two trials; one in September 2020 examining Miricorlilant and another in October 2019 involving the same therapy. Additionally, Janssen Scientific Affairs wrapped up their trial for D/C/F/TAF FDC in July 2020. These important studies contribute to our understanding of weight gain and hold promise for developing effective treatments to address this complex issue.